Roche Holding AG said a Japanese court ruled in favor of Chugai Pharmaceutical Co. Ltd. in a patent infringement case relating to hemophilia A drug Hemlibra versus Irish biotech Shire Plc.

The Tokyo District Court dismissed Shire's claims that Hemlibra, also known as emicizumab or ACE910, infringes patents held by Shire units Baxalta Inc. and Baxalta GmbH.

Shire was also seeking a preliminary injunction in the U.S. against Roche units Chugai and Genentech to limit sales of Hemlibra, which obtained U.S. Food and Drug Administration approval in November 2017.

Hemlibra has also received approvals from the European Medicines Agency and most recently Japan's Ministry of Health, Labour and Welfare.